Nemtabrutinib (MK-1026)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Nemtabrutinib (MK-1026), covering 2024-10-03 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) [Phase 3]